Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis
Respiratory syncytial virus (RSV)-associated acute respiratory infection (ARI) is an underrecognized cause of illness in older adults.
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus antigens could form the basis for a universal influenza virus vaccine that has the potential to elicit long-lasting, broadly cross-reactive immune responses.
How does a virus cause disease after transmission?
In this fascinating episode pathomechanism is explained and we learn how recent research has shown that acute virus infections may cause long-term health impairments. Even mild flu during pregnancy can affect susceptibility to disease in offspring.
FluCov: combining data from around the world to understand the impact of COVID-19 on influenza activity
The FluCov Epi-Bulletin provides an overview of the number of positive cases of influenza and SARS-CoV-2 and the percentage of specimens that tested positive from January 2019 onwards in 22 countries across most regions of the world.
National influenza surveillance systems in five European countries: a qualitative comparative framework based on WHO guidance
A new framework can be used to compare influenza surveillance systems qualitatively between countries to allow the identification of structural differences as well as to evaluate adherence to WHO guidance. The framework may be adapted for other infectious
Addressing COVID-19 vaccine hesitancy
This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.
How COVID-19 shaped mental health: from infection to pandemic effects
The Coronavirus Disease 2019 (COVID-19) pandemic has threatened global mental health, both indirectly via disruptive societal changes and directly via neuropsychiatric sequelae after SARS-CoV-2 infection.
Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return
Due to non-pharmaceutical intervention measures the global influenza burden decreased substantially; but with lifting of restrictions a rebound in other respiratory virus pathogens is both plausible and likely.
Infectious diseases and cognition: do we have to worry?
Age-related physiological changes, particularly immune system decline, may contribute to greater vulnerability to infectious diseases in older individuals.
Older adults and COVID-19 vaccines
What do we know so far about older adults and COVID-19 vaccines? How long does the effect of the vaccine last and how successful have countries been in vaccinating older adults? WHO’s Dr Katherine O’Brien explains in Science in 5
ESWI Young Scientists Network
ESWI launches the call for application for the Claude Hannoun prize for Best Body of Work and the Young Scientist Innovative Award.